|
|
原发性胆汁性胆管炎的流行病学、发病机制及治疗进展
|
Abstract:
原发性胆汁性胆管炎是一种慢性自身免疫性胆汁淤积性疾病，主要发生在中老年女性，PBC的发病率和患病率在不同地区和时期差异性较大。原发性胆汁性胆管炎的发病机制尚不明确，现普遍认为PBC的发病涉及遗传因素、环境因素和免疫因素。目前，除了熊去氧胆酸(UDCA)、奥贝胆酸以及贝特类药物被批准用于PBC患者的治疗，更多的新型药物以及治疗方法正处于临床研发的不同阶段。
Primary biliary cholangitis is a chronic autoimmune cholestasis disease, mainly occurring in middle-aged and elderly women. The incidence and prevalence of PBC vary greatly in different regions and periods. The pathogenesis of primary biliary cholangitis is still unclear, but it is generally believed that the pathogenesis of PBC involves genetic factors, environmental factors and immune factors. At present, in addition to Ursodeoxycholic Acid (UDCA), obecholic acid and bate drugs are approved for the treatment of PBC patients, more new drugs and treatments are in different stages of clinical research and development.
| [1] | Selmi, C., Bowlus, C.L., Gershwin, M.E. and Coppel, R.L. (2011) Primary Biliary Cirrhosis. The Lancet, 377, 1600-1609. https://doi.org/10.1016/s0140-6736(10)61965-4 |
| [2] | Bhandari, B.M., Bayat, H. and Rothstein, K.D. (2011) Primary Biliary Cirrhosis. Gastroenterology Clinics of North America, 40, 373-386. https://doi.org/10.1016/j.gtc.2011.03.008 |
| [3] | Lee, H.E., Churg, A., Ryu, J.H., Bilawich, A.M., Larsen, B.T., Tazelaar, H.D., et al. (2018) Histopathologic Findings in Lung Biopsies from Patients with Primary Biliary Cholangitis. Human Pathology, 82, 177-186. https://doi.org/10.1016/j.humpath.2018.07.021 |
| [4] | Trivella, J., John, B.V. and Levy, C. (2023) Primary Biliary Cholangitis: Epidemiology, Prognosis, and Treatment. Hepatology Communications, 7, e0179. https://doi.org/10.1097/hc9.0000000000000179 |
| [5] | Lv, L., Fang, D., Shi, D., Chen, D., Yan, R., Zhu, Y., et al. (2016) Alterations and Correlations of the Gut Microbiome, Metabolism and Immunity in Patients with Primary Biliary Cirrhosis. Environmental Microbiology, 18, 2272-2286. https://doi.org/10.1111/1462-2920.13401 |
| [6] | Xin, L. and Xin, Y. (2023) Genetic Predisposition of the Gastrointestinal Microbiome and Primary Biliary Cholangitis: A Bi-Directional, Two-Sample Mendelian Randomization Analysis. Frontiers in Endocrinology, 14, Article 1225742. https://doi.org/10.3389/fendo.2023.1225742 |
| [7] | Houri, I. and Hirschfield, G.M. (2024) Primary Biliary Cholangitis. Clinics in Liver Disease, 28, 79-92. https://doi.org/10.1016/j.cld.2023.06.006 |
| [8] | Metcalf, J., Bhopal, R., Gray, J., Howel, D. and James, O. (1997) Incidence and Prevalence of Primary Biliary Cirrhosis in the City of Newcastle Upon Tyne, England. International Journal of Epidemiology, 26, 830-836. https://doi.org/10.1093/ije/26.4.830 |
| [9] | Colapietro, F., Bertazzoni, A. and Lleo, A. (2022) Contemporary Epidemiology of Primary Biliary Cholangitis. Clinics in Liver Disease, 26, 555-570. https://doi.org/10.1016/j.cld.2022.06.001 |
| [10] | Lleo, A., Wang, G., Gershwin, M.E. and Hirschfield, G.M. (2020) Primary Biliary Cholangitis. The Lancet, 396, 1915-1926. https://doi.org/10.1016/s0140-6736(20)31607-x |
| [11] | Lv, T., Chen, S., Li, M., Zhang, D., Kong, Y. and Jia, J. (2020) Regional Variation and Temporal Trend of Primary Biliary Cholangitis Epidemiology: A Systematic Review and Meta‐Analysis. Journal of Gastroenterology and Hepatology, 36, 1423-1434. https://doi.org/10.1111/jgh.15329 |
| [12] | Murillo Perez, C.F., Goet, J.C., Lammers, W.J., Gulamhusein, A., van Buuren, H.R., Ponsioen, C.Y., et al. (2018) Milder Disease Stage in Patients with Primary Biliary Cholangitis over a 44‐Year Period: A Changing Natural History. Hepatology, 67, 1920-1930. https://doi.org/10.1002/hep.29717 |
| [13] | Gulamhusein, A.F. and Hirschfield, G.M. (2019) Primary Biliary Cholangitis: Pathogenesis and Therapeutic Opportunities. Nature Reviews Gastroenterology & Hepatology, 17, 93-110. https://doi.org/10.1038/s41575-019-0226-7 |
| [14] | Gerussi, A., Asselta, R. and Invernizzi, P. (2022) Genetics of Primary Biliary Cholangitis. Clinics in Liver Disease, 26, 571-582. https://doi.org/10.1016/j.cld.2022.06.002 |
| [15] | Hirschfield, G. and Invernizzi, P. (2011) Progress in the Genetics of Primary Biliary Cirrhosis. Seminars in Liver Disease, 31, 147-156. https://doi.org/10.1055/s-0031-1276644 |
| [16] | Nakamura, M., Nishida, N., Kawashima, M., Aiba, Y., Tanaka, A., Yasunami, M., et al. (2012) Genome-Wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population. The American Journal of Human Genetics, 91, 721-728. https://doi.org/10.1016/j.ajhg.2012.08.010 |
| [17] | Liu, J.Z., Almarri, M.A., Gaffney, D.J., Mells, G.F., Jostins, L., Cordell, H.J., et al. (2012) Dense Fine-Mapping Study Identifies New Susceptibility Loci for Primary Biliary Cirrhosis. Nature Genetics, 44, 1137-1141. https://doi.org/10.1038/ng.2395 |
| [18] | Tsuchiya, N. and Ohashi, J. (2015) Human Immune System Diversity and Its Implications in Diseases. Journal of Human Genetics, 60, 655-656. https://doi.org/10.1038/jhg.2015.101 |
| [19] | Cordell, H.J., Fryett, J.J., Ueno, K., Darlay, R., Aiba, Y., Hitomi, Y., et al. (2021) An International Genome-Wide Meta-Analysis of Primary Biliary Cholangitis: Novel Risk Loci and Candidate Drugs. Journal of Hepatology, 75, 572-581. https://doi.org/10.1016/j.jhep.2021.04.055 |
| [20] | Asselta, R., Paraboschi, E.M., Gerussi, A., Cordell, H.J., Mells, G.F., Sandford, R.N., et al. (2021) X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 160, 2483-2495.E26. https://doi.org/10.1053/j.gastro.2021.02.061 |
| [21] | Tanaka, A., Ma, X., Takahashi, A. and Vierling, J.M. (2024) Primary Biliary Cholangitis. The Lancet, 404, 1053-1066. https://doi.org/10.1016/s0140-6736(24)01303-5 |
| [22] | Wijarnpreecha, K., Werlang, M., Panjawatanan, P., Kroner, P.T., Mousa, O.Y., Pungpapong, S., et al. (2019) Association between Smoking and Risk of Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal and Liver Diseases, 28, 197-203. https://doi.org/10.15403/jgld-181 |
| [23] | Prince, M.I., Ducker, S.J. and James, O.F.W. (2010) Case-Control Studies of Risk Factors for Primary Biliary Cirrhosis in Two United Kingdom Populations. Gut, 59, 508-512. https://doi.org/10.1136/gut.2009.184218 |
| [24] | Corpechot, C., Chrétien, Y., Chazouillères, O. and Poupon, R. (2010) Demographic, Lifestyle, Medical and Familial Factors Associated with Primary Biliary Cirrhosis. Journal of Hepatology, 53, 162-169. https://doi.org/10.1016/j.jhep.2010.02.019 |
| [25] | Gershwin, E.M., Selmi, C., Worman, H.J., Gold, E.B., Watnik, M., Utts, J., et al. (2005) Risk Factors and Comorbidities in Primary Biliary Cirrhosis: A Controlled Interview-Based Study of 1032 Patients. Hepatology, 42, 1194-1202. https://doi.org/10.1002/hep.20907 |
| [26] | Howel, D., Fischbacher, C.M., Bhopal, R.S., Gray, J., Metcalf, J.V. and James, O.F. (2000) An Exploratory Population-Based Case-Control Study of Primary Biliary Cirrhosis. Hepatology, 31, 1055-1060. https://doi.org/10.1053/he.2000.7050 |
| [27] | Shimoda, S., Nakamura, M., Ishibashi, H., Hayashida, K. and Niho, Y. (1995) HLA DRB4 0101-Restricted Immunodominant T Cell Autoepitope of Pyruvate Dehydrogenase Complex in Primary Biliary Cirrhosis: Evidence of Molecular Mimicry in Human Autoimmune Diseases. The Journal of Experimental Medicine, 181, 1835-1845. https://doi.org/10.1084/jem.181.5.1835 |
| [28] | Matsumoto, K., Ohfuji, S., Abe, M., Komori, A., Takahashi, A., Fujii, H., et al. (2021) Environmental Factors, Medical and Family History, and Comorbidities Associated with Primary Biliary Cholangitis in Japan: A Multicenter Case-Control Study. Journal of Gastroenterology, 57, 19-29. https://doi.org/10.1007/s00535-021-01836-6 |
| [29] | Huang, B., Lyu, Z., Qian, Q., Chen, Y., Zhang, J., Li, B., et al. (2022) NUDT1 Promotes the Accumulation and Longevity of CD103+ TRM Cells in Primary Biliary Cholangitis. Journal of Hepatology, 77, 1311-1324. https://doi.org/10.1016/j.jhep.2022.06.014 |
| [30] | Shimoda, S., Hisamoto, S., Harada, K., Iwasaka, S., Chong, Y., Nakamura, M., et al. (2015) Natural Killer Cells Regulate T Cell Immune Responses in Primary Biliary Cirrhosis. Hepatology, 62, 1817-1827. https://doi.org/10.1002/hep.28122 |
| [31] | Chen, R., Huang, B., Lian, M., Wei, Y., Miao, Q., Liang, J., et al. (2023) A + T Rich Interaction Domain Protein 3a (Arid3a) Impairs Mertk-Mediated Efferocytosis in Cholestasis. Journal of Hepatology, 79, 1478-1490. https://doi.org/10.1016/j.jhep.2023.08.016 |
| [32] | Li, Y., Li, Z., Chen, R., Lian, M., Wang, H., Wei, Y., et al. (2023) A Regulatory Variant at 19p13.3 Is Associated with Primary Biliary Cholangitis Risk and ARID3A Expression. Nature Communications, 14, Article No. 1732. https://doi.org/10.1038/s41467-023-37213-5 |
| [33] | Hohenester, S., de Buy Wenniger, L.M., Paulusma, C.C., van Vliet, S.J., Jefferson, D.M., Oude Elferink, R.P., et al. (2012) A Biliary HCO3− Umbrella Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Human Cholangiocytes. Hepatology, 55, 173-183. https://doi.org/10.1002/hep.24691 |
| [34] | Melero, S., Spirlì, C., Zsembery, Á., Medina, J.F., Joplin, R.E., Duner, E., et al. (2002) Defective Regulation of Cholangiocyte Cl−/HCO−3 and Na+/H+ Exchanger Activities in Primary Biliary Cirrhosis. Hepatology, 35, 1513-1521. https://doi.org/10.1053/jhep.2002.33634 |
| [35] | Erice, O., Munoz-Garrido, P., Vaquero, J., Perugorria, M.J., Fernandez-Barrena, M.G., Saez, E., et al. (2018) MicroRNA-506 Promotes Primary Biliary Cholangitis-Like Features in Cholangiocytes and Immune Activation. Hepatology, 67, 1420-1440. https://doi.org/10.1002/hep.29533 |
| [36] | 尤红, 段维佳, 李淑香, 等. 原发性胆汁性胆管炎的诊断和治疗指南(2021) [J]. 临床肝胆病杂志, 2022, 38(1): 35-41. |
| [37] | Hirschfield, G.M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., et al. (2017) EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis. Journal of Hepatology, 67, 145-172. https://doi.org/10.1016/j.jhep.2017.03.022 |
| [38] | Lindor, K.D., Bowlus, C.L., Boyer, J., Levy, C. and Mayo, M. (2019) Primary Biliary Cholangitis: Calcium-Induced O-GlcNAc-Dependent Signaling. Hepatology, 69, 394-419. https://doi.org/10.1002/hep.30145 |
| [39] | Hen, S., Duan, W.J., You, H., Ma, X. and Jia, J.D. (2022) Recommendations of APASL Clinical Practice Guidance: The Diagnosis and Management of Patients with Primary Biliary Cholangitis. Chinese Journal of Hepatology, 30, 196-198. https://doi.org/10.3760/cma.j.cn501113-20220208-00058 |
| [40] | Harms, M.H., van Buuren, H.R., Corpechot, C., Thorburn, D., Janssen, H.L.A., Lindor, K.D., et al. (2019) Ursodeoxycholic Acid Therapy and Liver Transplant-Free Survival in Patients with Primary Biliary Cholangitis. Journal of Hepatology, 71, 357-365. https://doi.org/10.1016/j.jhep.2019.04.001 |
| [41] | Kim, K. (2023) Diagnosis and Treatment of Primary Biliary Cholangitis. The Korean Journal of Gastroenterology, 81, 86-90. https://doi.org/10.4166/kjg.2023.002 |
| [42] | Laschtowitz, A., de Veer, R.C., Van der Meer, A.J. and Schramm, C. (2020) Diagnosis and Treatment of Primary Biliary Cholangitis. United European Gastroenterology Journal, 8, 667-674. https://doi.org/10.1177/2050640620919585 |
| [43] | Roberts, S.B., Ismail, M., Kanagalingam, G., Mason, A.L., Swain, M.G., Vincent, C., et al. (2020) Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. Hepatology Communications, 4, 1332-1345. https://doi.org/10.1002/hep4.1518 |
| [44] | Nevens, F., Andreone, P., Mazzella, G., Strasser, S.I., Bowlus, C., Invernizzi, P., et al. (2016) A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England Journal of Medicine, 375, 631-643. https://doi.org/10.1056/NEJMoa1509840 |
| [45] | Kowdley, K.V., Luketic, V., Chapman, R., Hirschfield, G.M., Poupon, R., Schramm, C., et al. (2018) A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis. Hepatology, 67, 1890-1902. https://doi.org/10.1002/hep.29569 |
| [46] | Colapietro, F., Gershwin, M.E. and Lleo, A. (2023) PPAR Agonists for the Treatment of Primary Biliary Cholangitis: Old and New Tales. Journal of Translational Autoimmunity, 6, Article ID: 100188. https://doi.org/10.1016/j.jtauto.2023.100188 |
| [47] | Corpechot, C., Poupon, R. and Chazouillères, O. (2019) New Treatments/Targets for Primary Biliary Cholangitis. JHEP Reports, 1, 203-213. https://doi.org/10.1016/j.jhepr.2019.05.005 |
| [48] | Nakai, S., Masaki, T., Kurokohchi, K., Deguchi, A. and Nishioka, M. (2000) Combination Therapy of Bezafibrate and Ursodeoxycholic Acid in Primary Biliary Cirrhosis: A Preliminary Study. The American Journal of Gastroenterology, 95, 326-327. https://doi.org/10.1111/j.1572-0241.2000.01667.x |
| [49] | Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., et al. (2018) A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. New England Journal of Medicine, 378, 2171-2181. https://doi.org/10.1056/nejmoa1714519 |
| [50] | Tanaka, A., Hirohara, J., Nakano, T., Matsumoto, K., Chazouillères, O., Takikawa, H., et al. (2021) Association of Bezafibrate with Transplant-Free Survival in Patients with Primary Biliary Cholangitis. Journal of Hepatology, 75, 565-571. https://doi.org/10.1016/j.jhep.2021.04.010 |
| [51] | Grigorian, A.Y., Mardini, H.E., Corpechot, C., Poupon, R. and Levy, C. (2015) Fenofibrate Is Effective Adjunctive Therapy in the Treatment of Primary Biliary Cirrhosis: A Meta-Analysis. Clinics and Research in Hepatology and Gastroenterology, 39, 296-306. https://doi.org/10.1016/j.clinre.2015.02.011 |
| [52] | Guo, C., Zhang, Y., He, L., Wang, F., Chen, K., Li, J., et al. (2015) Combination Therapy of Fenofibrate and Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to UDCA Monotherapy: A Meta-Analysis. Drug Design, Development and Therapy, 9, 2757-2766. https://doi.org/10.2147/dddt.s79837 |
| [53] | Kowdley, K.V., Bowlus, C.L., Levy, C., Akarca, U.S., Alvares-da-Silva, M.R., Andreone, P., et al. (2024) Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. New England Journal of Medicine, 390, 795-805. https://doi.org/10.1056/nejmoa2306185 |
| [54] | Hirschfield, G.M., Bowlus, C.L., Mayo, M.J., Kremer, A.E., Vierling, J.M., Kowdley, K.V., et al. (2024) A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. New England Journal of Medicine, 390, 783-794. https://doi.org/10.1056/nejmoa2312100 |
| [55] | Hirschfield, G.M., Beuers, U., Kupcinskas, L., Ott, P., Bergquist, A., Färkkilä, M., et al. (2021) A Placebo-Controlled Randomised Trial of Budesonide for PBC Following an Insufficient Response to UDCA. Journal of Hepatology, 74, 321-329. https://doi.org/10.1016/j.jhep.2020.09.011 |
| [56] | Guo, C., Zhang, H., Yang, J., Zhu, R., Zheng, Y., Dai, W., et al. (2015) Combination Therapy of Ursodeoxycholic Acid and Budesonide for PBC-AIH Overlap Syndrome: A Meta-Analysis. Drug Design, Development and Therapy, 9, 567-574. https://doi.org/10.2147/dddt.s74515 |
| [57] | Al‐Harthy, N., Kumagi, T., Coltescu, C. and Hirschfield, G.M. (2010) The Specificity of Fatigue in Primary Biliary Cirrhosis: Evaluation of a Large Clinic Practice. Hepatology, 52, 562-570. https://doi.org/10.1002/hep.23683 |
| [58] | Tsuda, M., Moritoki, Y., Lian, Z., Zhang, W., Yoshida, K., Wakabayashi, K., et al. (2012) Biochemical and Immunologic Effects of Rituximab in Patients with Primary Biliary Cirrhosis and an Incomplete Response to Ursodeoxycholic Acid. Hepatology, 55, 512-521. https://doi.org/10.1002/hep.24748 |
| [59] | Myers, R.P., Swain, M.G., Lee, S.S., Shaheen, A.A.M. and Burak, K.W. (2013) B-Cell Depletion with Rituximab in Patients with Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid. American Journal of Gastroenterology, 108, 933-941. https://doi.org/10.1038/ajg.2013.51 |
| [60] | Khanna, A., Jopson, L., Howel, D., Bryant, A., Blamire, A., Newton, J.L., et al. (2018) Rituximab for the Treatment of Fatigue in Primary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis): A Randomised Controlled Trial. Efficacy and Mechanism Evaluation, 5, 1-78. https://doi.org/10.3310/eme05020 |
| [61] | Yang, C., Ma, X., Tsuneyama, K., Huang, S., Takahashi, T., Chalasani, N.P., et al. (2014) IL-12/Th1 and IL-23/Th17 Biliary Microenvironment in Primary Biliary Cirrhosis: Implications for Therapy. Hepatology, 59, 1944-1953. https://doi.org/10.1002/hep.26979 |
| [62] | Hirschfield, G.M., Gershwin, M.E., Strauss, R., Mayo, M.J., Levy, C., Zou, B., et al. (2016) Ustekinumab for Patients with Primary Biliary Cholangitis Who Have an Inadequate Response to Ursodeoxycholic Acid: A Proof‐of‐Concept Study. Hepatology, 64, 189-199. https://doi.org/10.1002/hep.28359 |
